What Happened

Novartis announced final Phase III ALIGN results for Vanrafia (atrasentan), demonstrating slower kidney function decline in IgA nephropathy (IgAN) patients compared to placebo. The findings, published in The Lancet and presented at the European Renal Association Congress, showed sustained reductions in proteinuria and consistent benefits across kidney function measures.

Who Is Affected

This impacts adults with IgAN, a progressive autoimmune kidney disease affecting approximately 25 people per million annually. Up to 50% of patients with persistent proteinuria progress to kidney failure within 10-20 years, often requiring dialysis or transplantation.

Market Impact

• Vanrafia’s success positions it as a foundational therapy for IgAN.
• Novartis plans to seek traditional approval in 2026, expanding its market reach.
• The data reinforces the need for targeted therapies in IgAN management.

What to Watch

Monitor Novartis’s submission for traditional approval in 2026 and the adoption of Vanrafia in clinical practice. Additionally, watch for further innovations in kidney disease treatment as Novartis continues its commitment to long-term kidney protection.